Study: FES-PET helps predict response to breast cancer therapy

06/9/2010 | HealthImaging.com

PET scans using FES, an experimental imaging biomarker containing estradiol, an analog form of estrogen, showed that breast cancer patients who responded well to second-line aromatase inhibitor therapy had a longer survival rate than those who didn't respond well, according to a Canadian study. FES-PET could help foresee treatment results for these patients and allow clinicians to halt ineffective therapies and develop an alternative treatment plan earlier, a researcher said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN